Exelixis: cabozantinib-funded sales
Exelixis retains net product revenue guidance of $2.3B–$2.35B. Its outlook excludes potential zanzalintinib launch revenue; approval belongs in a separate regulatory question.
Exelixis / EXELPublic biotechEarningsDate to watch
What matters
Watch product sales, guidance and cash needs alongside the headline result. Company filings and the earnings release provide the primary evidence.
Primary evidence
Reporting date unconfirmed — research candidate
Exelixis Q3 2026 results and financial guidancePublished 2026-10-29
Potential outcome market
Will Exelixis 2026 net product revenue exceed $2.325 billion?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.